# Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

> **NCT02257528** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Recurrent Cervical Carcinoma
- Stage IV Cervical Cancer AJCC v6 and v7
- Stage IVA Cervical Cancer AJCC v6 and v7
- Stage IVB Cervical Cancer AJCC v6 and v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02257528
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-05-18
- **Primary completion:** 2019-03-05
- **Final completion:** 2027-03-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02257528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02257528, "Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02257528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*